Clinical Trial Update: Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes [Phase 2]

View source ↗

Summary

This Clinical Trial Update reports completion of a Phase 2 study evaluating the safety and efficacy of INGAP-Peptide in patients with Type 1 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• INGAP-Peptide (INGAP peptide)

Snippet

Sponsor: Exsulin Corporation | Conditions: Diabetes Mellitus, Insulin-Dependent | Phase 2 | Status: COMPLETED